Author Question: Which nursing consideration(s) would be taken into account prior to the administration of cisplatin ... (Read 48 times)

mspears3 · **on:** Jul 24, 2018

Which nursing consideration(s) would be taken into account prior to the administration of cisplatin IV? (Select all that apply.)

a. Review of laboratory data for presence of myelosuppression and hepatic and renal parameters
b. Administration of IV hydration as prescribed
c. Administration of epoetin alfa (Epogen)
d. Administration of prechemotherapy mesna (Mesnex)
e. Assessment for dermatologic conditions

Question 2

Major chemotherapeutic agents include (Select all that apply.)

a. alkylating agents.
b. antineoplastic antibiotics.
c. hormones.
d. antimetabolites.
e. antinuclear antibodies.
f. chelating agents.

fauacakatahaias · **Reply #1 on:** Jul 24, 2018

Answer to Question 1

ANS: A, B, D
Premedication nursing considerations regarding cisplatin, an alkylating agent, include checking laboratory reports for baseline data reflecting hepatic and renal function and baseline hematologic studies that reflect the degree of myelosuppression present before initiating chemotherapy, assessing patient hydration and the health care provider's orders for oral and IV hydration instructions before drug therapy, and administering prechemotherapy drugs including mesna, ondansetron, and antianxiety drugs. Epogen is given to treat anemia associated with chemotherapy; it is not given before administration of chemotherapy. Dermatologic assessment is not necessary before administering cisplatin.

Answer to Question 2

ANS: A, B, C, D
Alkylating agents, antineoplastic antibiotics, hormones, and antimetabolites are considered major chemotherapeutic agents. Antinuclear antibodies are antibodies produced by the immune system that attack the body's own tissues instead of foreign toxins. They are frequently present in people with systemic lupus erythematosus and, less commonly, in other diseases. Chelating agents are used to detoxify a patient from heavy metal poisoning.